Author:
Wallis Christopher J.D.,Klaassen Zachary,Bhindi Bimal,Ye Xiang Y.,Chandrasekar Thenappan,Farrell Ann M.,Goldberg Hanan,Boorjian Stephen A.,Leibovich Bradley,Kulkarni Girish S.,Shah Prakesh S.,Bjarnason Georg A.,Heng Daniel Y.C.,Satkunasivam Raj,Finelli Antonio
Reference44 articles.
1. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018
2. Survival and prognostic startitifcation of 670 patients with advanced renal cell carcinoma;Motzer;J Clin Oncol,1999
3. Exelixis Annouces U.S. FDA Approval of CABOMETYX (caboantinib) tablets for previously untreated advanced renal cell carcinoma;Business Wire.,2017
4. LBA5 - CheckMate 214: Efficacy and safety of nivolumab 1 ipilimumab (N1I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups;Escudier;Ann Oncol,2017
5. IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma;Motzer;J Clin Oncol,2018
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献